Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.

PubWeight™: 0.90‹?›

🔗 View Article (PMC 2746603)

Published in Br J Cancer on May 20, 2002

Authors

M Lotem1, T Peretz, O Drize, Z Gimmon, D Ad El, R Weitzen, H Goldberg, I Ben David, D Prus, T Hamburger, E Shiloni

Author Affiliations

1: Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel 91120. lotem@isdn.net.il

Articles cited by this

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60

Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg (1995) 4.37

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol (1994) 2.10

The induction of hapten-specific T cell tolerance by using hapten-modified lymphoid cells. I. Characteristics of tolerance induction. J Immunol (1976) 1.68

A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg (1992) 1.50

Antibodies to normal human melanocytes in vitiligo. J Exp Med (1983) 1.50

Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol (1998) 1.29

Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res (1986) 1.25

Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol (1998) 1.04

Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Ann Oncol (2000) 1.01

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol (1997) 0.96

Active-specific immunotherapy for melanoma. J Clin Oncol (1990) 0.95

Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol (1993) 0.95

Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res (1991) 0.91

Prognosis of skin melanoma with regional node metastases (stage II). J Surg Oncol (1984) 0.88

Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer (1992) 0.85

Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line. Clin Cancer Res (1997) 0.85

Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. Clin Cancer Res (1998) 0.84

Major histocompatibility complex class I restricted cytotoxic T cells specific for natural melanoma peptides recognize unidentified shared melanoma antigen(s). Cancer Res (1999) 0.83

Autologous, hapten-modified vaccine as a treatment for human cancers. Vaccine (2001) 0.80

Treatment of human melanoma with a hapten-modified autologous vaccine. Ann N Y Acad Sci (1993) 0.79

Complete spontaneous regression of cutaneous primary malignant melanoma. Plast Reconstr Surg (1992) 0.78

Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients. Cancer Immunol Immunother (1986) 0.78

Suppression of the responsiveness of lymphocytes from cancer patients triggered by co-culture with autologous tumor-derived cells. J Immunol (1983) 0.77

Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine. Cancer Immunol Immunother (1996) 0.77

Adjuvant therapy of melanoma: at what cost? J Clin Oncol (2001) 0.77

Articles by these authors

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21

The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet (1995) 5.83

Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med (1999) 4.22

Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A (2000) 3.36

Health of the public. The academic response. Health of the Public Mission Statement Working Group. JAMA (1992) 2.95

Intra-abdominal lymphangioma. Br J Surg (1989) 2.92

The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet (1997) 2.28

Preventive content of adult primary care: do generalists and subspecialists differ? Am J Public Health (1984) 2.06

Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol (2000) 1.98

Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol (1987) 1.85

Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol (2001) 1.69

Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol (1996) 1.59

Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol (2000) 1.52

Parasitic ovarian dermoid tumor of the omentum-A review of the literature and report of two new cases. Eur J Obstet Gynecol Reprod Biol (1998) 1.52

Ovarian tissue banking in patients with Hodgkin's disease: is it safe? Fertil Steril (1998) 1.46

Conservative treatment of a traumatic tear of the left hepatic duct: case report. J Trauma (1996) 1.43

Acute surgical abdominal disease in chronic schizophrenic patients: a unique clinical problem. Isr J Med Sci (1990) 1.42

Fatal necrotizing fasciitis following suction-assisted lipectomy. Ann Plast Surg (1988) 1.42

A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer (2004) 1.41

Paracecal hernia: a cause of intestinal obstruction. Dis Colon Rectum (1986) 1.41

Arrhythmias and left ventricular asynergy in the prolapsing mitral leaflet syndrome. Am J Cardiol (1972) 1.40

Hemangiopericytoma of the third ventricle. Case report. J Neurosurg (1999) 1.37

Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis (1995) 1.34

Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer (1998) 1.32

CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer (2001) 1.27

Left ventricular abnormalities in prolapsed mitral leaflet syndrome. Review of eighty-seven cases. Circulation (1973) 1.22

Right atrial thrombi are related to indwelling central venous catheter position: insights into time course and possible mechanism of formation. Am Heart J (1998) 1.21

The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet (1999) 1.19

Bordetella pertussis infection: a cause of persistent cough in adults. Med J Aust (1987) 1.16

Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril (1996) 1.16

Evaluation of ECG criteria for P-wave abnormalities. Am Heart J (1967) 1.16

Growing teratoma syndrome vs chemotherapeutic retroconversion: case report and review of the literature. Gynecol Oncol (2004) 1.14

Laparoscopic vs open adrenalectomy for benign adrenal neoplasm. Surg Endosc (2001) 1.12

Laparoscopic cholecystectomy in octogenarians. Surg Endosc (2003) 1.12

Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. Br J Cancer (2006) 1.12

Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut (1999) 1.11

Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol (1989) 1.09

Successful treatment of bacterial endocarditis due to pseudomonas aeruginosa. Am J Cardiol (1966) 1.08

Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood (1996) 1.08

Tumor suppressor p53 regulates heparanase gene expression. Oncogene (2006) 1.07

Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol (1987) 1.06

Preimplantation genetic diagnosis for BRCA1/2--a novel clinical experience. Prenat Diagn (2009) 1.05

Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors. Cancer Res (1988) 1.05

Molecular properties and involvement of heparanase in cancer progression and mammary gland morphogenesis. J Mammary Gland Biol Neoplasia (2001) 1.04

Expression of the imprinted H19 oncofetal RNA in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol (1999) 1.04

H19 and IGF2 gene expression in human normal, hyperplastic, and malignant endometrium. Int J Gynecol Cancer (2004) 1.03

Pancreaticojejunostomy versus controlled pancreaticocutaneous fistula in pancreaticoduodenectomy for periampullary carcinoma. Am J Surg (1995) 1.03

Cholestatic syndromes in infancy: diagnostic value of serum bile acid pattern and cholestyramine administration. Pediatr Res (1973) 1.03

Immortalized cementoblasts and periodontal ligament cells in culture. Bone (1999) 1.02

Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. J Skin Cancer (2013) 1.02

Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer (1991) 1.02

Primary colorectal sarcoma. A retrospective review and prognostic factor study of 50 consecutive patients. Arch Surg (1990) 1.00

Synchronous colorectal and renal carcinomas: a noteworthy clinical entity. Report of five cases. Dis Colon Rectum (2000) 1.00

Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur J Cancer Clin Oncol (1989) 0.98

Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. Am J Clin Nutr (1995) 0.98

Mechanism of the hypertriglyceridemia induced by tumor necrosis factor administration to rats. Biochim Biophys Acta (1989) 0.98

Cerebral hemodynamics in the diagnosis of normal pressure hydrocephalus. Neurology (1984) 0.98

Iatrogenic arteriovenous fistula: a complication of percutaneous subclavian vein puncture. Chest (1975) 0.98

Late thrombosis of the aortic Bjork-Shiley prosthesis. Its clinical recognition and management. Chest (1976) 0.98

Electronic patient records and the impact of the Internet. Int J Med Inform (2000) 0.97

Abdominal compartment syndrome due to delayed identification of a ureteral perforation following abdomino-perineal resection for rectal carcinoma. Int J Urol (1997) 0.96

Requirements for transforming growth factor-beta regulation of the pro-alpha 2(I) collagen and plasminogen activator inhibitor-1 promoters. J Biol Chem (1995) 0.96

Juvenile leg ulceration in beta-thalassemia major and intermedia. Plast Reconstr Surg (1982) 0.96

Percutaneous needle biopsy of the transplanted kidney: technique and complications. Am J Kidney Dis (1989) 0.96

Diagnosis of severe tricuspid regurgitation. Chest (1982) 0.96

Primary progressive freezing gait. Mov Disord (1993) 0.96

Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. Clin Oncol (R Coll Radiol) (2007) 0.96

Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br J Cancer (2007) 0.95

A deletion/insertion mutation in the BRCA2 gene in a breast cancer family: a possible role of the Alu-polyA tail in the evolution of the deletion. Genes Chromosomes Cancer (2001) 0.95

Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol (2006) 0.95

Toxic idiopathic megacolon: fatal outcome in a mentally retarded adolescent. Dis Colon Rectum (1978) 0.94

Silent coronary artery-left ventricular fistula: a disorder of the thebesian system? Angiology (1978) 0.94

Infections caused by Pseudomonas pickettii in association with permanent indwelling intravenous devices: four cases and a review. Clin Infect Dis (1993) 0.93

The effect of decentralized education versus increased supply on practice location. Experience with physician assistants and nurse practitioners in California, 1972-1982. Med Care (1984) 0.93

Merkel cell tumor masquerading as granulation tissue on a teenager's toe. Am J Dermatopathol (1992) 0.93

Blood-brain barrier derangement in sepsis: cause of septic encephalopathy? Am J Surg (1981) 0.93

Radiocurability of microscopic disease in childhood rhabdomyosarcoma with radiation doses less than 4,000 cGy. J Clin Oncol (1990) 0.92

Update on nasopharyngeal carcinoma in northern Israel. Strahlenther Onkol (1994) 0.92

Isolation of promoter for cytosolic phospholipase A2 (cPLA2). Biochim Biophys Acta (1994) 0.92

Preoperative localization of parathyroid adenoma in patients with concomitant thyroid nodular disease. World J Surg (2000) 0.91

Aberrant conduction due to retrograde activation of the right bundle branch. J Electrocardiol (1970) 0.91

Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. Hum Hered (2001) 0.91

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer (2004) 0.91

Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol (1994) 0.90

EZH2 promotes a bi-lineage identity in basal-like breast cancer cells. Oncogene (2013) 0.90

Tension haemothorax: an unusual complication of central vein catheterization. Injury (1985) 0.90

Combined endoscopic and surgical management of Mirizzi syndrome. Surg Endosc (1999) 0.90

Aneurysm of the membranous portion of the ventricular septum. Am J Cardiol (1969) 0.90

Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet (1998) 0.90

Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel. Gynecol Oncol (2003) 0.90

Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor. J Immunol (1993) 0.89

Phosphorylation of a K+ channel alpha subunit modulates the inactivation conferred by a beta subunit. Involvement of cytoskeleton. J Biol Chem (1996) 0.89

Effects of epinephrine on resisitive and compliant properties of the canine vasculature. J Appl Physiol (1975) 0.88

Congenital subclavian steal syndrome associated with right aortic arch. Br Heart J (1968) 0.88